Hanyi Yao , Zixi Xiao , Shufang Liu , Xingjian Gao , Zehong Wu , Dongping Li , Zhangqing Yi , Haojie Zhou , Weizhi Zhang
{"title":"通过RNA测序和生物信息学分析筛选脓毒症诱发心肌功能障碍的新型疾病基因","authors":"Hanyi Yao , Zixi Xiao , Shufang Liu , Xingjian Gao , Zehong Wu , Dongping Li , Zhangqing Yi , Haojie Zhou , Weizhi Zhang","doi":"10.1016/j.ygeno.2024.110911","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>There is still a lack of effective treatment for sepsis-induced myocardial dysfunction (SIMD), while the pathogenesis of SIMD still remains largely unexplained.</p></div><div><h3>Methods</h3><p>RNA sequencing results (GSE267388 and GSE79962) were used for cross-species integrative analysis. Bioinformatic analyses were used to delve into function, tissue- and cell- specificity, and interactions of genes. External datasets and qRT-PCR experiments were used for validation. L1000 FWD was used to predict targeted drugs, and 3D structure files were used for molecular docking.</p></div><div><h3>Results</h3><p>Based on bioinformatic analyses, ten differentially expressed genes were selected as genes of interest, seven of which were verified to be significantly differential expression. Bucladesine was considered as a potential targeted drug for SIMD, which banded to seven target proteins primarily by forming hydrogen bonds.</p></div><div><h3>Conclusion</h3><p>It was considered that <em>Cebpd</em>, <em>Timp1</em>, <em>Pnp</em>, <em>Osmr</em>, <em>Tgm2</em>, <em>Cp,</em> and <em>Asb2</em> were novel disease genes, while bucladesine was a potential therapeutic drug, of SIMD.</p></div>","PeriodicalId":12521,"journal":{"name":"Genomics","volume":"116 5","pages":"Article 110911"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0888754324001320/pdfft?md5=cca2d967557214ef34591f2420bd9b5c&pid=1-s2.0-S0888754324001320-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Screening of novel disease genes of sepsis-induced myocardial Disfunction by RNA sequencing and bioinformatics analysis\",\"authors\":\"Hanyi Yao , Zixi Xiao , Shufang Liu , Xingjian Gao , Zehong Wu , Dongping Li , Zhangqing Yi , Haojie Zhou , Weizhi Zhang\",\"doi\":\"10.1016/j.ygeno.2024.110911\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>There is still a lack of effective treatment for sepsis-induced myocardial dysfunction (SIMD), while the pathogenesis of SIMD still remains largely unexplained.</p></div><div><h3>Methods</h3><p>RNA sequencing results (GSE267388 and GSE79962) were used for cross-species integrative analysis. Bioinformatic analyses were used to delve into function, tissue- and cell- specificity, and interactions of genes. External datasets and qRT-PCR experiments were used for validation. L1000 FWD was used to predict targeted drugs, and 3D structure files were used for molecular docking.</p></div><div><h3>Results</h3><p>Based on bioinformatic analyses, ten differentially expressed genes were selected as genes of interest, seven of which were verified to be significantly differential expression. Bucladesine was considered as a potential targeted drug for SIMD, which banded to seven target proteins primarily by forming hydrogen bonds.</p></div><div><h3>Conclusion</h3><p>It was considered that <em>Cebpd</em>, <em>Timp1</em>, <em>Pnp</em>, <em>Osmr</em>, <em>Tgm2</em>, <em>Cp,</em> and <em>Asb2</em> were novel disease genes, while bucladesine was a potential therapeutic drug, of SIMD.</p></div>\",\"PeriodicalId\":12521,\"journal\":{\"name\":\"Genomics\",\"volume\":\"116 5\",\"pages\":\"Article 110911\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0888754324001320/pdfft?md5=cca2d967557214ef34591f2420bd9b5c&pid=1-s2.0-S0888754324001320-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genomics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0888754324001320\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomics","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0888754324001320","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Screening of novel disease genes of sepsis-induced myocardial Disfunction by RNA sequencing and bioinformatics analysis
Background
There is still a lack of effective treatment for sepsis-induced myocardial dysfunction (SIMD), while the pathogenesis of SIMD still remains largely unexplained.
Methods
RNA sequencing results (GSE267388 and GSE79962) were used for cross-species integrative analysis. Bioinformatic analyses were used to delve into function, tissue- and cell- specificity, and interactions of genes. External datasets and qRT-PCR experiments were used for validation. L1000 FWD was used to predict targeted drugs, and 3D structure files were used for molecular docking.
Results
Based on bioinformatic analyses, ten differentially expressed genes were selected as genes of interest, seven of which were verified to be significantly differential expression. Bucladesine was considered as a potential targeted drug for SIMD, which banded to seven target proteins primarily by forming hydrogen bonds.
Conclusion
It was considered that Cebpd, Timp1, Pnp, Osmr, Tgm2, Cp, and Asb2 were novel disease genes, while bucladesine was a potential therapeutic drug, of SIMD.
期刊介绍:
Genomics is a forum for describing the development of genome-scale technologies and their application to all areas of biological investigation.
As a journal that has evolved with the field that carries its name, Genomics focuses on the development and application of cutting-edge methods, addressing fundamental questions with potential interest to a wide audience. Our aim is to publish the highest quality research and to provide authors with rapid, fair and accurate review and publication of manuscripts falling within our scope.